Abstract Library

#4141 BRAF/MEK combination treatment in a patient with BRAF mutated neuroendocrine carcinoma

Introduction: Preclinical studies indicate that BRAF V600E mutation is a druggable target in neuroendocrine carcinomas (NEC). Indeed, there are a few case reports that describe clinical response from BRAF inhibitor treatment of colorectal NEC.

Conference:

Presenting Author: Zhang L

Authors: Falkman L, Zhang L, Welin S, Crona J,

Keywords: Neuroendocrine carcinoma, BRAF V600E, Dabrafenib, Trametinib,

#3810 A patient with BRAF V600E mutated colon-NEC showing response to BRAF- and MEK inhibitors

Introduction: Preclinical studies have reported that the BRAF V600E mutation is a druggable target in colorectal neuroendocrine carcinomas (NECs). At least one case report has presented clinical success in the treatment of colorectal NEC using a BRAF inhibitor.

Conference:

Presenting Author:

Authors: Falkman L, Sundin A, Crona J, Wallin G, Welin S,

Keywords: neuroendocrine carcinoma, BRAF V600E, dabrafenib, trametinib, colorectal nec,

#3735 Longitudinal changes in Ki-67 index in a prospective cohort of pancreatic neuroendocrine tumors

Introduction: The biology of pancreatic neuroendocrine tumors (panNET) can change over time. In retrospective cohorts, many panNETs showed longitudinal increases in Ki-67 index leading to a higher tumor grade and poor survival. However, data from prospective studies are lacking, and non-invasive methods of determining tumor grade progression are needed in order to monitor and guide further treatment.

Conference:

Presenting Author: Mollazadegan K

Authors: Mollazadegan K, Botling J, Welin S, Zhang L, Eriksson B,

Keywords: neuroendocrine tumor, pancreas, high-grade, poor prognosis, biomarker, Ki-67,

#3721 No multiple endocrine neoplasia type 1 (MEN1) Patient died from pancreaticoduodenal neuroendocrine tumor – Results from long-term follow-up of the Uppsala model of early diagnosis and treatment

Introduction: Progression of pancreaticoduodenal neuroendocrine tumor (P-NET) disease is the main death cause among MEN1 carriers. Although surgery is the only cure, indications vary substantially between centers. The Uppsala model of MEN1 management encompasses early diagnosis and treatment, aiming at lifelong malignancy prevention with preserved endocrine function. During three decades, all MEN1 patients harbouring P-NETs of at least 1 cm have been considered for surgery.

Conference:

Presenting Author:

Authors: Bajic D, Kjaer J, Welin S, Norlén O, Öberg K,

Keywords: multiple endocrine neoplasia type 1, pancreatic neuroendocrine tumor, indication for surgery, malignancy prevention,

#3265 Assessment of hormonal levels as prognostic markers and of their optimal cut-offs in small intestinal neuroendocrine tumors grade 2

Introduction: Multianalytes might be used to monitor small intestinal neuroendocrine tumors (siNETs) Grade 2 in the future, but blood chromogranin A (CgA) and urine 5HIAA are still widely used in clinical praxis.

Conference: 18th Annual ENETS Concerence (2021)

Presenting Author:

Authors: Papantoniou D, Grönberg M, Landerholm K, Welin S, Ziolkowska B,

Keywords: Chromogranin A, 5HIAA, small intestinal neuroendocrine tumor, biomarker, carcinoid, cut-offs,